Published in J Urol on October 01, 2006
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology (2010) 2.57
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol (2011) 2.01
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol (2007) 1.60
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys (2013) 1.40
Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys (2010) 1.30
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol (2008) 1.25
A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys (2008) 1.16
Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol (2014) 1.13
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol (2012) 1.10
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther (2011) 1.08
Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol (2011) 1.06
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol (2014) 1.06
Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med (2011) 1.00
Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect? Front Oncol (2011) 0.99
Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J (2012) 0.99
Low risk prostate cancer in men under age 65: the case for definitive treatment. Urol Oncol (2007) 0.96
Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study. Front Oncol (2014) 0.95
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol (2012) 0.95
Current status of intensity-modulated radiation therapy (IMRT). Int J Clin Oncol (2007) 0.94
Active surveillance or active treatment in localized prostate cancer? Dtsch Arztebl Int (2009) 0.91
Analysis of inter-fraction setup errors and organ motion by daily kilovoltage cone beam computed tomography in intensity modulated radiotherapy of prostate cancer. Radiat Oncol (2012) 0.91
The clinical case for proton beam therapy. Radiat Oncol (2012) 0.90
Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res (2009) 0.90
Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol (2010) 0.90
Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol (2012) 0.89
Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol (2009) 0.89
Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One (2013) 0.87
Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only? Radiat Oncol (2008) 0.86
Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer. Onco Targets Ther (2014) 0.86
Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer (2012) 0.85
Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy. Int J Clin Oncol (2008) 0.85
Promise and pitfalls of heavy-particle therapy. J Clin Oncol (2014) 0.85
Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer. Front Oncol (2015) 0.84
Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer (2012) 0.84
Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol (2015) 0.84
The Prediction of Radiotherapy Toxicity Using Single Nucleotide Polymorphism-Based Models: A Step Toward Prevention. Semin Radiat Oncol (2015) 0.83
Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer (2013) 0.83
Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol (2009) 0.83
Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre. Cancers (Basel) (2011) 0.80
Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer. Strahlenther Onkol (2009) 0.80
Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. Radiat Oncol (2012) 0.80
Reducing rectal injury during external beam radiotherapy for prostate cancer. Nat Rev Urol (2013) 0.80
Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys (2007) 0.80
Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy. Strahlenther Onkol (2013) 0.80
Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age. J Radiat Res (2015) 0.79
Real-time prostate motion assessment: image-guidance and the temporal dependence of intra-fraction motion. BMC Med Phys (2013) 0.79
High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control. Int J Clin Exp Med (2010) 0.79
A study on rectal dose measurement in phantom and in vivo using Gafchromic EBT3 film in IMRT and CyberKnife treatments of carcinoma of prostate. J Med Phys (2013) 0.79
Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. J Exp Clin Cancer Res (2013) 0.79
Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiat Oncol (2013) 0.79
A systems biology approach to radiation therapy optimization. Radiat Environ Biophys (2010) 0.78
Saudi Oncology Society clinical management guidelines for prostate cancer. Urol Ann (2011) 0.78
Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. J Radiat Oncol (2016) 0.78
Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World J Urol (2008) 0.76
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment. Strahlenther Onkol (2016) 0.76
Bladder cancer after radiotherapy for prostate cancer. Rev Urol (2013) 0.75
Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol (2013) 0.75
The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer. Prostate Cancer (2012) 0.75
Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes. Radiat Oncol (2015) 0.75
Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer. Prostate Int (2015) 0.75
Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer. Yonsei Med J (2015) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2014) 0.75
Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol (2012) 0.75
Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer? Front Oncol (2016) 0.75
Comparison of hybrid volumetric modulated arc therapy (VMAT) technique and double arc VMAT technique in the treatment of prostate cancer. Radiol Oncol (2015) 0.75
Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma. Radiat Oncol J (2016) 0.75
Prostate cancer: quality of life after radiation and androgen deprivation. Nat Rev Urol (2009) 0.75
The impact of financial interest in intensity-modulated radiation therapy on the utilization of radiation therapy for treatment of newly diagnosed prostate cancer: a single center experience. ISRN Urol (2012) 0.75
Prostate cancer: in favour of active surveillance--functional outcomes matter. Nat Rev Urol (2013) 0.75
Evaluation of different set-up error corrections on dose-volume metrics in prostate IMRT using CBCT images. J Radiat Res (2014) 0.75
Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study. Radiat Oncol J (2016) 0.75
Percutaneous radiotherapy for low-risk prostate cancer: options for 2007. World J Urol (2007) 0.75
Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy. Technol Cancer Res Treat (2016) 0.75
[Radiotherapy for prostate cancer]. Wien Med Wochenschr (2007) 0.75
Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med (2017) 0.75
Effect of modern, high-quality prostate intensity-modulated radiation therapy on outcome: Evidence from a community radiation oncology program. Mol Clin Oncol (2017) 0.75
Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma. Int J Clin Oncol (2015) 0.75
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys (2002) 2.65
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology (2010) 2.57
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer (2010) 2.42
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol (2013) 2.33
Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 2.28
Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol (2007) 2.20
State of teledermatology programs in the United States. J Am Acad Dermatol (2012) 2.20
Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol (2008) 2.08
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2005) 2.04
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol (2011) 2.01
Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys (2009) 1.97
Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine (2013) 1.96
A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976) (2010) 1.91
Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol (2008) 1.91
Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys (2008) 1.85
Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol (2011) 1.69
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Comparison of end normal inspiration and expiration for gated intensity modulated radiation therapy (IMRT) of lung cancer. Radiother Oncol (2005) 1.58
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer (2005) 1.57
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.56
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys (2007) 1.54
Optimization of collimator trajectory in volumetric modulated arc therapy: development and evaluation for paraspinal SBRT. Int J Radiat Oncol Biol Phys (2010) 1.50
Snake oil: who's buying and who's selling? In regard to Glatstein: "The return of the snake oil salesmen," IJROBP 2003;55:561-562. Int J Radiat Oncol Biol Phys (2003) 1.42
Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantation. Brachytherapy (2009) 1.42
Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh. Int J Radiat Oncol Biol Phys (2004) 1.37
Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) (2009) 1.31
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.28
Integrating respiratory gating into a megavoltage cone-beam CT system. Med Phys (2006) 1.28
Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys (2006) 1.22
Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.19
Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro Oncol (2013) 1.18
Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. Acta Neurochir (Wien) (2011) 1.18
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res (2013) 1.16
Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.16
Challenges of local recurrence and cure in low grade malignant tumors of the spine. Spine (Phila Pa 1976) (2009) 1.15
Choosing an intensity-modulated radiation therapy technique in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Accurate setup of paraspinal patients using a noninvasive patient immobilization cradle and portal imaging. Med Phys (2005) 1.13
Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys (2010) 1.13
Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys (2003) 1.11
Motion monitoring for cranial frameless stereotactic radiosurgery using video-based three-dimensional optical surface imaging. Med Phys (2011) 1.11
Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int (2014) 1.10
Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.10
IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys (2002) 1.09
Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy (2010) 1.09
International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2012) 1.08
Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient. J Neurosurg Spine (2010) 1.07
Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine (2010) 1.06
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys (2009) 1.05
Acquisition of MV-scatter-free kilovoltage CBCT images during RapidArc™ or VMAT. Radiother Oncol (2011) 1.04
Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology (2007) 1.04
Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine (2010) 1.03
Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.02
Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2012) 1.00
Vertical and horizontal growth features of superficial esophageal squamous cell carcinomas: histopathological evaluation of endoscopically resected specimens. Virchows Arch (2002) 1.00
Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol (2003) 1.00
Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. Radiother Oncol (2007) 0.99
Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys (2005) 0.99
Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience. Brachytherapy (2011) 0.99
Implanted cardiac defibrillator care in radiation oncology patient population. Int J Radiat Oncol Biol Phys (2008) 0.98
A simplified intensity modulated radiation therapy technique for the breast. Med Phys (2002) 0.98
The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist (2013) 0.97
Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.96
Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction. Radiother Oncol (2010) 0.96
Choreographing couch and collimator in volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys (2011) 0.95
Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother Oncol (2009) 0.95
Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med Phys (2006) 0.94
Reduction of organ motion in lung tumors with respiratory gating. Lung Cancer (2005) 0.94
Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases. Int J Radiat Oncol Biol Phys (2010) 0.92
Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 0.91
Low-dose megavoltage cone-beam computed tomography for lung tumors using a high-efficiency image receptor. Med Phys (2006) 0.90
ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. J Am Coll Radiol (2012) 0.90